A Study of E7080 Alone, and in Combination With Everolimus in Subjects With Unresectable Advanced or Metastatic Renal Cell Carcinoma Following One Prior Vascular Endothelial Growth Factor (VEGF)-Targeted Treatment

Completed · Phase 1/Phase 2

Conditions studied: Metastatic Renal Cell Carcinoma

In brief

This is an open-label, multicenter, Phase 1b/2 study of lenvatinib alone and in combination with everolimus in subjects with unresectable advanced or metastatic renal cell carcinoma following one prior VEGF-targeted treatment.

Key facts

Study ID

NCT01136733

Run by

Eisai Inc.

People needed

173

Starts

2010-08-05

Expected to finish

2018-02-08

Last updated by the study team

2019-02-27

Who can join

Age: 18 and older, up to 99. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Study site — Tucson, Arizona, United States
• Study site — Orange, California, United States
• Study site — San Diego, California, United States
• Study site — Tampa, Florida, United States
• Study site — Joliet, Illinois, United States
• Study site — Louisville, Kentucky, United States
• Study site — Annapolis, Maryland, United States
• Study site — Bethesda, Maryland, United States
• Study site — Boston, Massachusetts, United States
• Study site — Tupelo, Mississippi, United States
• Study site — New York, New York, United States
• Study site — Tulsa, Oklahoma, United States
• Study site — Charleston, South Carolina, United States
• Study site — Dallas, Texas, United States
• Study site — Brno, Czechia
• Study site — Olomouc, Czechia
• Study site — Prague, Czechia
• Study site — Gdansk, Poland
• Study site — Lodz, Poland
• Study site — Szczecin, Poland
• Study site — Warsaw, Poland
• Study site — Barcelona, Spain
• Study site — Córdoba, Spain
• Study site — Madrid, Spain
• Study site — Pamplona, Spain

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.